Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease, Cachexia, and Cardioprotection Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATGL/PNPLA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PNPLA2/ATGL Full-Length & Catalytic Domain Proteins (WT & Catalytic Dead Mutant S47A). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW Confirmed. Human/Mouse/Cyno orthologs available. | View ATGL Products |
| Gene Delivery | PNPLA2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines in hepatic, adipocyte, and cardiomyocyte models. HEK293 expressed. | View ATGL Products |
| Benchmark Ab | Anti-PNPLA2/ATGL Recombinant Antibody (Research Grade). For Western, ELISA, IP, IHC positive controls. Sequence Verified. | View ATGL Products |
| Validator | PNPLA2/ATGL siRNA Set. For knockdown verification in lipid droplet clearance & lipolysis assays. | View ATGL Products |
| Related Target: ABHD5 (CGI-58) | Essential co-activator of ATGL. Required for functional enzymatic complex reconstitution. | View ABHD5 Products |
| Related Target: LIPE (HSL) | Downstream lipase; critical for selectivity counter-screening and pathway studies. | View LIPE Products |
| Related Target: PNPLA3 (Adiponutrin) | High homology patatin domain target. Essential for off-target liability screening in NASH/metabolic disease. | View PNPLA3 Products |
| Related Target: PNPLA1 | Close structural homolog; required for comprehensive PNPLA subfamily off-target assessment. | View PNPLA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PNPLA Subfamily Selectivity (PNPLA1/PNPLA3/PNPLA8 off-target liability) | High-purity human PNPLA2 WT & Mutant + homolog panel (PNPLA1, PNPLA3, PNPLA8) >95% purity, Mass Spec & Sequence Verified. |
| Co-activator Dependency (ABHD5) | Sequence Verified ABHD5 recombinant protein available to reconstitute native ATGL lipolysis complex. |
| Cross-Species Translation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity for bridging assays. |
| Lack of Reliable Controls & Cellular Target Engagement | PNPLA2 ORF Lentivirus for stable overexpression; PNPLA2 siRNA for loss-of-function validation; Catalytically inactive mutant (S47A) as negative control. Endotoxin Controlled. |
| False Positives in Enzymatic Screens | Validated siRNA, catalytically dead mutant, and high-purity proteins reduce aggregation/artifact hits. |
Live ATGL/PNPLA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials for PNPLA2
- ➤ Latest Resistance Research on ATGL
- ➤ Recent Patent Filings for ATGL inhibitors
Global Clinical Landscape & Future Outlook
The race for ATGL/PNPLA2 therapeutics is intensifying, with major players shifting focus from broad metabolic modulation (e.g., obesity, NAFLD) to tissue-specific lipolysis inhibition for cancer cachexia, heart failure, and lipotoxic cardiomyopathy. First-generation small molecule inhibitors, such as Atglistatin derivatives, are advancing in preclinical and early Phase I/II trials. The next wave of R&D is targeting tissue-specific delivery strategies — adipose- or muscle-specific for cachexia, and liver-specific to avoid systemic off-target effects. Emerging modalities include allosteric modulators and antisense oligonucleotides (Secarna, Ionis) that enable precise knockdown in target organs. Combinatorial therapies with GLP-1 receptor agonists are also anticipated to mitigate muscle wasting during weight loss.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Novo Nordisk, Eli Lilly, Early Biotech | Cancer Cachexia, Heart Failure, Metabolic Syndrome | Enzymatic Selectivity (Need High-Purity ATGL & LIPE proteins) + Co-activator reconstitution |
| Allosteric Modulators | Emerging Biotech | Cardioprotection (lipotoxicity) | Conformational Binding Assay (Need WT & Mutant Proteins) |
| Antisense Oligonucleotides / siRNA | Secarna Pharmaceuticals, Ionis, Novartis | Cardiometabolic Syndrome, Liver-targeted Metabolic Disease | Knockdown Validation (Need standardized siRNA & benchmark Antibodies) |
| PROTACs | Preclinical Innovators | Metabolic Dysregulation | Degradation Tracking (Need specific Abs and stable lentiviral cell lines) |